The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035, registering a compound annual growth rate (CAGR) of 7.4% over the forecast period

Metric	Value
Market Size in 2025	USD 54.50 billion
Projected Market Size in 2035	USD 111.3 billion
CAGR (2025 to 2035)	7.4%

Country-Wise Outlook

Country	CAGR (2025 to 2035)
United States	6.7%

Country	CAGR (2025 to 2035)
United Kingdom	6.2%

Country	CAGR (2025 to 2035)
European Union	6.4%

Country	CAGR (2025 to 2035)
Japan	6.1%

Country	CAGR (2025 to 2035)
South Korea	6.6%

The global vaccine market size was valued at USD 59.83 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 136.46 Billion by 2033, exhibiting a CAGR of 9.12% during 2025-2033. Asia-Pacific currently dominates the market, holding a significant market share of over 38.9% in 2024. The implementation of stringent regulations promoting vaccination adoption among individuals, several advances in biotechnology and vaccine development techniques, and growing health awareness among the population about the importance of vaccination are some of the major factors propelling the market.

The Preventive Vaccines Market report segments the industry into By Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, mRNA Vaccines, Other Vaccine Types), By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), COVID-19, Other Disease Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 160.22 billion at a CAGR of 23.1% between 2024 and 2029.

The market is experiencing significant growth, driven by increased funding for research and development, leading to the launch of new vaccines. One of the most promising trends in this market is the development of nanoparticle vaccines, which offer enhanced immunogenicity and improved delivery systems. This trend is particularly evident in the development of nanoparticle vaccines, which offer enhanced efficacy and safety. However, the high cost of research, development, and manufacturing poses a significant challenge for market players. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These costs can be attributed to the complex production processes involved in vaccine creation, as well as the need for rigorous clinical trials to ensure safety and efficacy. 
However, the high cost of vaccine research, development, and manufacturing remains a significant challenge for market participants. Despite this, the market presents numerous opportunities for companies seeking to capitalize on the growing demand for vaccines, particularly in emerging economies with rising healthcare expenditures. Strategic partnerships, collaborations, and acquisitions are key strategies for companies looking to navigate the competitive landscape and stay ahead of the curve.
Overall, the market is poised for continued growth, with significant opportunities for innovation and investment in the coming years. Companies that can effectively address the challenges of cost and regulatory compliance while delivering high-quality, effective vaccines will be well-positioned to succeed.

What will be the Size of the Vaccines Market during the forecast period?

Request Free Sample

The market driven by the continuous development of immunization programs and the pursuit of vaccine equity. Immunological memory, antibody response, and cost-effectiveness analysis are key factors influencing market growth. Vaccine supply chain, efficacy testing, preservation, patent, and licensing are essential aspects of the market. Nanotechnology and universal vaccines are emerging trends, aiming to improve vaccine accessibility and quality control. Vaccine manufacturing, regulatory approval, and economic impact are crucial elements in the market, with intellectual property, vaccine shelf life, and vaccine development pipeline being significant factors.
Vaccine innovation and vaccine safety monitoring are essential for addressing disease burden and ensuring potency, stability, and sterility. Vaccine logistics and vaccine stability are critical for successful distribution and administration, while vaccine safety monitoring emphasizes the importance of ongoing surveillance and immune response assessment. 

How is this Vaccines Industry segmented?

The vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Subunit vaccines
  Live attenuated vaccines
  Inactivated vaccines
  Toxoid vaccines
  Others


End-user

  Hospitals
  Clinics


Technology

  mRNA vaccines
  Viral vector vaccines
  Protein based vaccines
  DNA vaccines
  Others


Route Of Administration

  Intramuscular
  Subcutaneous
  Oral
  Intranasal
  Others


Disease Type

  Influenza
  Human papillomavirus
  Hepatitis
  Measles
  mumps
  rubella
  Others


Age Group

  Pediatric
  Adult
  Adolescent
  Geriatric


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The subunit vaccines segment is estimated to witness significant growth during the forecast period.

Subunit vaccines, integral components of the healthcare system's disease prevention strategy, employ specific antigenic pieces of a pathogen, such as proteins, sugars, or capsids, to induce a robust immune response. These vaccines, including the mRNA vaccines, are designed to target specific components of the pathogen, making them highly effective in preventing infections. The development process involves identifying and isolating these antigenic components, followed by formulation and rigorous testing to ensure safety and efficacy. For instance, in the realm of disease outbreak prevention, a phase 3 trial for the subunit TB vaccine candidate M72/AS01E was initiated in March 2024 in South Africa.

This trial aims to evaluate the vaccine's efficacy in preventing the progression from latent TB to active pulmonary TB, contributing to herd immunity and ultimately, disease surveillance and vaccine distribution within the healthcare system.

The Vaccines Market report segments the industry into By Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, Recombinant Vaccines, Toxoid Vaccines, and more), By Type (Monovalent Vaccines, Multivalent Vaccines), By Disease Indication (DTP, Hepatitis, Herpes Zoster, HPV, Influenza, and more), By Route of Administration (Oral Administration, and more), By End-User, and By Geography.

The statistic shows the size of the total global vaccine market in 2017 and a forecast for 2028. In 2017, the total global market was valued at around **** billion U.S. dollars. It is estimated that the market will grow to nearly *** billion U.S. dollars by 2028.

The global Vaccine market size reached USD 69.2 Billion and is expected to reach USD 134.7 Billion in 2034 registering a CAGR of 8.7%. Vaccine industry report classifies global market by share, trend, growth and based on type, patient type, disease, technology, and region

As per Cognitive Market Research's latest published report, the Global mRNA vaccine market size was $1.45 Billion in 2022 and it is forecasted to reach $3.86 Billion by 2030. mRNA vaccine Industry's Compound Annual Growth Rate will be 12.8 % from 2023 to 2030. Whereas a Self-amplifying mRNA Vaccines Market Share was 61.25%, a leading type of mRNA Vaccine. Market Dynamics of mRNA Vaccine Market

Key Drivers for mRNA Vaccine Market

Rise in the prevalence of infectious diseases: Recently, emerging and re-emerging infectious diseases are posing a public health threat across the globe. This era has witnessed a wave of severe infectious disease outbreaks which has had a devastating impact on lives and livelihoods around the globe. It has been studied that increasing resistances, international traveling, the risk of bio-war attacks, and infectious diseases concern the whole world. The infectious agents not only disrupt cell growth and proliferation but also weaken the immune system which considerably decreases the body’s ability to fight cancer-causing infections. Some viruses, bacteria and parasites also cause chronic inflammation, leading to cancers.

Mounting R&D Investment: Health is a prime focused parameter for regulatory bodies across the world. With the increasing prevalence of communicable and non-communicable diseases, the rate of mortality has been increased dramatically. Hence the authorities are focusing on improving the healthcare system. With the increasing healthcare requirements and associated priorities for research and development, governments and companies are investing more monetary funds into the research and development activities. For instance, the United States has invested $194.2 billion in medical and health research and development which was grew by 6.4% from 2017 to 2018.

Key Restraints for mRNA Vaccine Market

High Development and Manufacturing Costs: The production of mRNA vaccines necessitates specialized facilities, specific raw materials, and cold-chain logistics, resulting in elevated production expenses. The requirement for ultra-low temperature storage (-70°C for certain vaccines) complicates distribution in regions with limited resources. Although increasing production capacity may lead to cost reductions over time, the initial financial investments continue to pose a challenge for numerous pharmaceutical companies and developing countries.

Regulatory and Safety Concerns: In spite of their effectiveness, mRNA vaccines encounter skepticism due to their innovative mechanism and infrequent side effects such as myocarditis. Regulatory agencies enforce rigorous approval procedures, which can delay market entry. Additionally, public hesitancy, exacerbated by misinformation, affects adoption rates, necessitating comprehensive awareness initiatives to foster trust in this technology.

Key Trends for mRNA Vaccine Market

Expansion Beyond Infectious Diseases: Researchers are investigating the potential of mRNA vaccines for treating cancer, autoimmune diseases, and genetic disorders. Personalized cancer vaccines, which are tailored to target specific tumor antigens, are demonstrating encouraging outcomes in clinical trials. This diversification has the potential to greatly broaden the market, positioning mRNA as a fundamental element of next-generation therapeutics beyond conventional vaccines.

Improvements in Stability and Delivery Systems: Recent advancements in lipid nanoparticles (LNPs) and alternative delivery techniques are improving the stability of mRNA vaccines, thereby decreasing the necessity for extreme cold storage. Additionally, companies are working on self-amplifying mRNA (saRNA) vaccines, which require smaller doses and promote longer-lasting immunity. These innovations will enhance accessibility, particularly in remote and resource-constrained areas. Introduction of mRNA Vaccine

mRNA is a biological substance that is given in a series of shots to protect the body from developing a disease. It works by triggering the immune system to create antibodies. These antibodies then fight bacteria and viruses that cause disease. Most mRNA vaccines are multi-antigen vaccines, where mRNA has advantages over peptide-based vaccines. For more than 30 years, healthcare providers are using this technology to prevent infectious and oncological diseases. They are also studying mRNA vaccines to treat diseases like multiple sclero...

The global H1N1 vaccines market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.6 Billion by 2033, exhibiting a growth rate (CAGR) of 4.03% during 2025-2033. The increasing healthcare concerns, significant medical advancements, improving healthcare systems, and rising awareness about the importance of H1N1 vaccines are some of the major factors propelling the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 3.9 Billion
Market Forecast in 2033	USD 5.6 Billion
Market Growth Rate 2025-2033	4.03%

IMARC Group provides an analysis of the key trends in each segment of the global H1N1 vaccines market report, along with forecasts at the global and regional levels from 2025-2033. Our report has categorized the market based on vaccine type, key brands and market type.

The demand for human vaccines in China has been growing along with a rising public healthcare expenditure. By 2030, China's vaccination market size was projected to reach *** billion yuan in terms of sales revenue. Currently, domestic vaccines have been dominating the market supply in China.

The global cancer vaccines market is estimated to reach a valuation of USD 11.29 billion in 2025. It is expected to reach USD 27.95 billion by 2035, reflecting a CAGR of 12% during the forecast period between 2025 and 2035.

Metrics	Values
Industry Size (2025E)	USD 11.29 billion
Industry Value (2035F)	USD 27.95 billion
CAGR	12%

Global Vaccine market size 2021 was recorded $65.931 Billion whereas by the end of 2025 it will reach $81.9 Billion. According to the author, by 2033 Vaccine market size will become $126.379. Vaccine market will be growing at a CAGR of 5.572% during 2025 to 2033.

The global veterinary vaccines market is projected to expand from USD 9.92 billion in 2025 to USD 16.34 billion by 2035, reflecting a CAGR of 5.2%.

Attributes	Key Insights
Estimated Size, 2025	USD 9.92 billion
Projected Size, 2035	USD 16.34 billion
Value-based CAGR (2025 to 2035)	5.2%

Country-wise Insights

Countries	Value CAGR (2025 to 2035)
USA	6.1%
China	7.9%
Germany	5.0%
UK	5.7%
Japan	4.5%
India	7.5%

As of 2024, the global market for cancer vaccines was valued at nearly 10 billion U.S. dollars. It is expected to increasearound 16 billion U.S. dollars by 2029. This statistic illustrates forecasts of the cancer vaccine market worldwide in 2024 and 2029.

The Travel Vaccines Market report segments the industry into By Type (Cholera, Diptheria Pertussis Tetanus (DPT), Encephalitis, Hepatitis A, Meningococcal, Rabies, Typhoid, Yellow Fever, Other Types), By Travel Type (Domestic, Outbound), By Vaccination Center (Hospitals, Travel Clinics, Other Vaccination Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

The global pediatric vaccines market size reached USD 39.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 72.7 Billion by 2033, exhibiting a growth rate (CAGR) of 6.89% during 2025-2033. The growing conduction of vaccination programs, increasing focus on combination vaccines, and rising partnerships between pharmaceutical companies and healthcare organizations for fast-tracking the development and distribution of vaccines are some of the major factors propelling the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 39.7 Billion
Market Forecast in 2033	USD 72.7 Billion
Market Growth Rate 2025-2033	6.89%

IMARC Group provides an analysis of the key trends in each segment of the global pediatric vaccines market report, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on type, technology, and application.

In 2020, the market size of the vaccine industry in China surpassed ** billion yuan. In the past decade, the industry grew significantly, with the sales revenue of class II vaccines, which were not covered by mandatory vaccination programs of the government, more than doubled since 2015. The market is expected to grow further, to an overall size exceeding *** billion yuan in 2025.

This statistic describes the size of the total global human vaccine market from 2014 to 2024. It is projected that the global vaccine market will generate nearly ** billion U.S. dollars by 2024. That would be more than double the size in 2016.

According to Cognitive Market Research, the global Inactivated Vaccines Market size will be USD 42514.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 8.00% from 2025 to 2033.

North America held the major market share for more than 37% of the global revenue with a market size of USD 15730.48 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2033.
Europe accounted for a market share of over 29% of the global revenue with a market size of USD 12329.29 million.
APAC held a market share of around 24% of the global revenue with a market size of USD 10203.55 million in 2025 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2025 to 2033.
South America has a market share of more than 3.8% of the global revenue with a market size of USD 1615.56 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2025 to 2033.
Middle East had a market share of around 4.00% of the global revenue and was estimated at a market size of USD 1700.59 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2033.
Africa had a market share of around 2.20% of the global revenue and was estimated at a market size of USD 935.33 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
Radiation Method is the fastest growing segment of the Inactivated Vaccines Market industry

Market Dynamics of Inactivated Vaccines Market

Key Drivers for Inactivated Vaccines Market

Increasing prevalence of infectious diseases globally fuels the market demand

The growing global burden of infectious diseases such as influenza, hepatitis, rabies, polio, and emerging zoonotic infections has significantly bolstered the demand for inactivated vaccines. According to the World Health Organization (WHO), the seasonal influenza affects about 1 billion people worldwide annually, causing 3 to 5 million severe cases and 290,000 to 650,000 deaths. It spreads via respiratory droplets and surfaces, with symptoms like fever and cough appearing within 1 to 4 days. Vaccination is the best prevention, recommended yearly for everyone over six months, especially high-risk groups. Flu seasons peak in winter months in temperate regions and occur year-round in tropical areas. These vaccines are particularly preferred in population groups requiring high safety profiles, including children, the elderly, and immunocompromised individuals. The resurgence of certain preventable diseases, owing to declining vaccination rates in some regions and the emergence of new viral strains, has further necessitated reliable and safe immunization options. Governments and international bodies such as the World Health Organization and UNICEF continue to emphasize immunization through national and regional programs, further propelling market demand. The increased frequency of epidemics and pandemics has also reinforced the need for scalable and broadly applicable inactivated vaccine solutions.

https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)

Expanding geriatric population with higher susceptibility to infections is expected to drive the market

The global rise in the aging population has emerged as a critical factor driving the growth of the inactivated vaccines market. Elderly individuals are more susceptible to various infectious diseases due to immunosenescence, an age-related decline in immune function. As a result, they require effective yet safe vaccines that do not pose risks of replication-induced complications, making inactivated vaccines an optimal choice. Moreover, increasing life expectancy and greater healthcare access among the elderly are contributing to higher vaccination rates. Healthcare providers are also proactively recommending inactivated vaccines as part of preventive care strategies for the aging population. Government immunization schedules in many countries now include inactivated vaccines targeting diseases like influenza and pneumococcal infections specifically for older adults.

Restraint Factor for the Inactivated Vaccines Market

High cost and longer production timelines for inactivated vaccines limit market growth

The manufacturing of inactivated vaccines involves complex procedures, including pathogen cultivation, inactivation, purification, formulation, and rigorous quality control, which substantially increase production...

By 2035, the Vaccine Market is estimated to expand to USD 155.4 Billion, showcasing a robust CAGR of 6.2% between 2025 and 2035, starting from a valuation of USD 80.2 Billion in 2024.